A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels

NCT01770743 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

168

Enrollment

INDUSTRY

Sponsor class

Conditions

Anthrax

Interventions

BIOLOGICAL: AV7909
BIOLOGICAL: BioThrax

Sponsor

Emergent BioSolutions

Collaborators

[object Object]